The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a multistep method for transfecting mouse stem cells with native human chromosomes, where they are stably maintained and can be manipulated to replace native DNA with synthetic DNA. The engineered chromosomes can then be transferred into a human cell in place of the native chromosomes.

Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.

Aimedbio Inc. raised ₩70.73 billion (US$48.24 million) in its Dec. 4 IPO, marking the largest Kosdaq listing this year.

The BioWorld Neurological Diseases Index continued the recovery noted at the end of August, closing November with a gain of 2.64%.